울트라제닉스제약(주)
DE ˙ DB ˙ US90400D1081
€19.00 ↓ -0.11 (-0.60%)
2026-06-05
주가
SecurityDE:UP0 / Ultragenyx Pharmaceutical Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership1,772,184 shares
Latest Disclosed Value $ 37,127,255
Millennium Management Llc ownership in UP0 / Ultragenyx Pharmaceutical Inc.

On May 15, 2026 - Millennium Management Llc filed a 13F-HR form disclosing ownership of 1,772,184 shares of Ultragenyx Pharmaceutical Inc. (DE:UP0) valued at $29,949,910 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 880,644 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of 101.24% during the quarter. The current value of the position is $33,671,496 USD.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (UP0) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:UP0 / Ultragenyx Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,772,184 891,540 101.24 37,127 83.31 0.0155
2026-02-17 2025-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 880,644 781,431 787.63 20,255 578.75 0.0085
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 99,213 -387,128 -79.60 2,984 -83.13 0.0013
2025-08-14 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 486,341 -226,052 -31.73 17,683 -31.45 0.0085
2025-05-15 2025-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 712,393 15,157 2.17 25,796 -12.06 0.0137
2025-02-14 2024-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 697,236 -13,453 -1.89 29,333 -25.70 0.0143
2024-11-14 2024-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 710,689 -1,140,045 -61.60 39,479 -48.10 0.0187
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 1,850,734 1,142,829 161.44 76,065 130.14 0.0352
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 707,905 679,353 2,379.35 33,052 2,321.39 0.0141
2024-02-14 2023-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 28,552 -80,396 -73.79 1,365 -64.85 0.0006
2023-11-14 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 108,948 53,503 96.50 3,884 51.86 0.0020
2023-08-14 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 55,445 -706,402 -92.72 2,558 -91.63 0.0013
2023-05-15 2023-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 761,847 -10,880 -1.41 30,550 -14.66 0.0175
2023-02-14 2022-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 772,727 477,325 161.58 35,800 192.65 0.0198
2022-11-14 2022-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 295,402 171,571 138.55 12,233 65.58 0.0072
2022-08-15 2022-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 123,831 116,413 1,569.33 7,388 1,270.69 0.0046
2022-05-16 2022-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 7,418 -55,822 -88.27 539 -89.86 0.0003
2022-02-14 2021-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 63,240 -44,524 -41.32 5,318 -45.28 0.0027
2021-11-15 2021-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 107,764 -455,623 -80.87 9,719 -81.91 0.0058
2021-08-16 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 563,387 563,387 53,719 0.0330
2021-05-17 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -2,095 -100.00 0 -100.00
2021-02-16 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 2,095 -3,858 -64.81 290 -40.70 0.0002
2020-11-16 2020-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,953 -49,570 -89.28 489 -88.74 0.0006
2020-08-14 2020-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 55,523 42,129 314.54 4,343 629.92 0.0060
2020-05-14 2020-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 13,394 13,394 -75.88 595 -86.30 0.0013
2020-02-14 2019-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -5,813 -100.00 0 -100.00
2019-11-14 2019-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 5,813 5,813 248 0.0004
2019-02-15 2018-12-31 13F/A-1 ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -17,362 -100.00 0 -100.00
2018-11-14 2018-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 17,362 17,362 1,325 0.0016
2018-08-14 2018-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -300,260 -100.00 0 -100.00
2018-05-15 2018-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 300,260 176,425 142.47 15,310 166.59 0.0204
2018-02-14 2017-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 123,835 37,315 43.13 5,743 24.63 0.0079
2017-11-14 2017-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 86,520 86,520 -30.13 4,608 -19.76 0.0070
2017-08-14 2017-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -3,920 -100.00 0 -100.00
2017-05-15 2017-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 3,920 3,920 266 0.0005
2017-02-14 2016-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 0 -10,000 -100.00 0 -100.00
2016-11-14 2016-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 10,000 -451,245 -97.83 709 -96.86 0.0012
2016-08-15 2016-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 461,245 175,350 61.33 22,559 24.64 0.0516
2016-05-16 2016-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 285,895 91,705 47.22 18,100 -16.91 0.0452
2016-02-16 2015-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 194,190 -347,499 -64.15 21,784 -58.24 0.0458
2015-11-16 2015-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 541,689 57,509 11.88 52,170 5.23 0.1010
2015-08-14 2015-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 484,180 -497,666 -50.69 49,575 -18.68 0.0938
2015-05-15 2015-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 981,846 674,563 219.52 60,963 352.11 0.1134
2015-02-17 2014-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 307,283 303,283 7,582.07 13,484 5,866.37 0.0286
2014-11-14 2014-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 4,000 -10,350 -72.13 226 -64.91 0.0006
2014-08-14 2014-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 14,350 -63,781 -81.63 644 -83.14 0.0018
2014-05-15 2014-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM 90400D108 78,131 78,131 3,820 0.0111
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-14 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 20,000 727 n/a n/a n/a
2024-08-14 2024-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-15 2024-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 200,300 9,352 n/a n/a n/a
2023-11-14 2023-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 15,000 692 n/a n/a n/a
2021-08-16 2021-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-05-17 2021-03-31 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 65,000 790.41 7,401 632.05 n/a n/a n/a
2021-02-16 2020-12-31 13F ULTRAGENYX PHARMACEUTICAL IN COM Call 7,300 1,011 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-14 2025-09-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-14 2025-06-30 13F ULTRAGENYX PHARMACEUTICAL IN COM Put 15,500 564 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.